Literature DB >> 3276643

Topically applied cyclosporine in azone prolongs corneal allograft survival.

C Newton1, B M Gebhardt, H E Kaufman.   

Abstract

The purpose of this study was to develop and test a topical ocular delivery system for the immunosuppressive drug cyclosporine. To this end, cyclosporine was dissolved in the penetration enhancer, Azone, and applied topically to allografted rabbit eyes. The concentration of cyclosporine in the cornea, the aqueous humor, and blood of the treated rabbits was determined by radioimmunoassay. The effect of the cyclosporine-Azone preparation on the survival of corneal allografts was assessed by clinical evaluation of the grafts and by histopathologic and immunohistologic evaluation of the cellular infiltrate in the grafts. Clinically significant concentrations of cyclosporine were measured in the treated corneas but little or no drug was found in the aqueous humor or blood of the treated animals. Cyclosporine in Azone resulted in suppression in the severity and incidence of graft rejection. The suppression of graft rejection was borne out by the immunohistologic observations. Cyclosporine-treated grafts contained significantly fewer infiltrating T lymphocytes than did the drug/solvent-treated allografts, indicating that the topical application of cyclosporine actively inhibited the entry of T cells into the grafts. This study, for the first time, presents a solvent that is apparently not toxic but is effective in delivering immunologically active concentrations of cyclosporine following topical application to the cornea.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3276643

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  8 in total

Review 1.  Experimental corneal allograft rejection.

Authors:  Bryan M Gebhardt; Weiyun Shi
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

2.  Ocular absorption of Pz-peptide and its effect on the ocular and systemic pharmacokinetics of topically applied drugs in the rabbit.

Authors:  Y B Chung; K Han; A Nishiura; V H Lee
Journal:  Pharm Res       Date:  1998-12       Impact factor: 4.200

Review 3.  Systemic cyclosporine and corneal transplantation.

Authors:  Mohammed Ziaei; Fatemeh Ziaei; Bita Manzouri
Journal:  Int Ophthalmol       Date:  2016-02       Impact factor: 2.031

4.  Prevention of experimental corneal allograft rejection in rabbits using cyclosporin-collagen shields.

Authors:  K Mahlberg; R J Uusitalo; B Gebhardt; H E Kaufman
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

5.  Influence of topical cyclosporine A and dissolvent on corneal epithelium permeability of fluorescein.

Authors:  J M Benítez del Castillo; A Castillo; N Toledano; S Durán; C del Aguila; M Otero; J García-Sanchez
Journal:  Doc Ophthalmol       Date:  1995       Impact factor: 2.379

6.  Different effects of absorption promoters on corneal and conjunctival penetration of ophthalmic beta-blockers.

Authors:  H Sasaki; Y Igarashi; T Nagano; K Nishida; J Nakamura
Journal:  Pharm Res       Date:  1995-08       Impact factor: 4.200

7.  Prolongation of corneal allograft survival by CTLA4-FasL in a murine model.

Authors:  Weiyun Shi; Min Chen; Lixin Xie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-05-31       Impact factor: 3.117

Review 8.  An overview on dry eye treatment: approaches for cyclosporin a delivery.

Authors:  Burçin Yavuz; Sibel Bozdağ Pehlivan; Nurşen Unlü
Journal:  ScientificWorldJournal       Date:  2012-04-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.